The EASi-HF study is testing whether a combination of two medicines, BI 690517 and empagliflozin, can help people with heart failure who have a left ventricular ejection fraction (LVEF) of 40% or more. Participants take either both medicines or a placebo and empagliflozin once a day, and their health is regularly monitored to see if the treatment is effective.